The Causes of the Charcot Syndrome

Clinics in Podiatric Medicine and Surgery

Volumn 25, Issue 1, 2008, Pages 29-42

  Jeffcoate, William ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTERY CALCIFICATION; BLOOD VESSEL REACTIVITY; BONE DENSITY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE PREDISPOSITION; DISLOCATION; FOOT EDEMA; FOOT FRACTURE; FOOT MALFORMATION; GENETIC PREDISPOSITION; HUMAN; HYPEREMIA; NEUROPATHIC JOINT DISEASE; NOCICEPTION; NONHUMAN; OSTEOPENIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ARTHROPATHY, NEUROGENIC; DIABETES COMPLICATIONS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SYNDROME;

EID: 37349092698     PISSN: 08918422     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpm.2007.10.003     Document Type: Review

References (61)

1. Jeffcoate W.J., Game F.L., and Cavanagh P.R. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 366 (2005) 2058-2061
2. Kon T., Cho T.J., Aizawa T., et al. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res 16 (2001) 1004-1014
3. Khosla S. Minireview: the OPG/RANK system. Endocrinology 142 (2001) 5050-5055
4. Hofbauer L.C., and Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification?. Lancet 358 (2001) 257-259
5. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
6. Hofbauer L.C., and Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. J Am Med Assoc 292 (2004) 490-495
7. Rogers A., and Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor-kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90 (2005) 6323-6331
8. Gerstenfeld L.C., Cho T.J., Kon T., et al. Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signalling. Cells Tissues Organs 169 (2001) 285-294
9. Saidenberg-Kermanac'h N., Bessis N., Cohen-Salal M., et al. Osteoprotegerin and inflammation. Eur Cytokine Netw 13 (2002) 144-153
10. Lam J., Abu-Amer Y., Nelson C.A., et al. Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. Ann Rheum Dis 61 (2002) 82-83
11. Sugawara J., Hayashi K., Kaneko F., et al. Reductions in basal limb blood flow and lumen diameter after short-term leg casting. Med Sci Sports Exerc 36 (2004) 1689-1694
12. Petrova N.L., Foster A.V., and Edmonds M.E. Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between Type 1 and Type 2 diabetes. Diabet Med 22 6 (2005) 756-761
13. Jirkowská A., Kasalický P., Boucek P., et al. Calcaneal ultrasonometry in patients with Charcot osteoarthropathy and its relationship with densitometry in the lumbar spine and femoral neck and with markers of bone turnover. Diabet Med 18 6 (2001) 495-500
14. Hastings M.K., Sinacore D.R., Fielder F.A., et al. Bone mineral density during total contact cast immobilization for a patient with neuropathic (Charcot) arthropathy. Phys Ther 85 3 (2005) 249-256
15. Game F., Catlow R., Jeffcoate W., et al. CDUK: a UK-wide, web-based survey of the management of the acute Charcot foot of diabetes. Diabetologia 50 Suppl 1 (2007) P1116
16. Jeffcoate W.J., Chipchase S.Y., Ince P., et al. Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures. Diabetes Care 29 8 (2006) 1784-1787
17. Shapiro S.A., Stansberry K.B., Hill M.A., et al. Normal blood flow response and vasomotion in the diabetic Charcot foot. J Diabetes Complications 12 (1998) 147-153
18. Veves A., Akbari C.M., Primavera J., et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 47 (1998) 457-463
19. Baker N., Green A., Krishnan S., et al. Microvascular and C-fiber function in diabetic Charcot neuro-arthropathy and diabetic peripheral neuropathy. Diabetes Care 30 12 (2007) 3077-3079
20. Charcot J.M. Sur quelques arthropathies qui paraiise dépendre d'une lésion du cerveau ou de la mouelle épinière. Arch Physiol Norm Pathlo 1 (1868) 161-178
21. Edmonds M.E., Roberts V.C., and Watkins P.J. Blood flow in the diabetic neuropathic foot. Diabetologia 22 1 (1982) 9-15
22. Cundy T., Edmonds M.E., and Watkins P.J. Osteopenia and metatarsal fractures in diabetic neuropathy. Diabet Med 2 (1985) 461-464
23. Kayath M.J., Dib S.A., and Viela J.G. Prevalence and magnitude of osteopenia associated with insulin-dependent diabetes mellitus. J Diabetes Complications 8 (1994) 97-104
24. Forst T., Pfutzner A., Kann P., et al. Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med 12 (1995) 874-879
25. Rix M., Andreasson H., and Eskilden P. Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care 22 (1999) 827-831
26. Ziegler R. Diabetes mellitus and bone metabolism. Horm Metab Res Suppl 26 (1992) 90-94
27. Léger J., Marinovic D., Alberti C., et al. Lower bone mineral content in children with type 1 diabetes mellitus is linked to female sex, low insulin-like growth factor type I levels, and high insulin requirement. J Clin Endocrinol Metab 91 10 (2006) 3947-3953
28. Jirkovska A., Bém R., Fejfarová V., et al. Longitudinal study of vitamin D insufficiency and its association with osteoclastic activity in patients with Charcot osteoarthropathy. Diabetes 55 Suppl 1 (2007) 260 0R
29. Psyrogiannis A., Kyriazooulou V., and Vagenakis A.G. Medial arterial calcification is frequently found in patients with microalbuminuria. Angiology 50 (1999) 971-975
30. Whitehouse F.W., and Weckstein M. On diabetic osteopathy: a radiographic study of 21 patients. Diabetes Care 1 (1978) 303-304
31. Edmonds M.E., Morrison N., Laws J.W., et al. Medial arterial calcification and diabetic neuropathy. Br Med J 284 (1982) 928-930
32. Lithner F., Hietala S.O., and Steen L. Skeletal lesions and arterial calcifications of the feet in diabetics. Acta Med Scand Suppl 687 (1984) 47-54
33. Gentile S., Bizarro A., Marmo R., et al. Medial arterial calcification and diabetic neuropathy. Acta Diabetol Lat 27 (1990) 243-253
34. Sinha S., Munichoodappa C., and Kozak G.P. Neuro-arthropathy (Charcot joints) in diabetes mellitus: a clinical study of 101 cases. Medicine (Baltimore) 51 (1972) 191-210
35. Clouse M.E., Gramm H.F., Legg M., et al. Diabetic osteoarthropathy: clinical and roentgenographic observations in 90 cases. Am J Roentgenol Radium Ther Nucl Med 121 (1974) 22-33
36. Knaggs R.I. Charcot joints. In: Knaggs R.I. (Ed). Inflammatory and toxic disorders of bone (1926), John Wright & Sons, Bristol (RI) 105-119
37. Schoppet M., Al-Fakhri N., Franke F.E., et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-κB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 89 (2004) 4104-4112
38. Abedin M., Tintut Y., and Demer L.L. Vascular calcification. Arterioscler Thromb Vasc Biol 24 (2004) 1161-1170
39. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95 (2004) 1046-1057
40. Hruska K.A., Mathew S., and Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 97 2 (2005) 105-114
41. Hayden M.R., Tyagi S.C., Kolb L., et al. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 4 1 (2005) 4
42. Galluzzi F., Stagi S., and Salti R. Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur J Endocrinol 153 6 (2005) 879-885
43. Xiang G.D., Sun H.L., and Zhao L.S. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Res Clin Pract 76 2 (2007) 199-206
44. Secchiero P., Corallini F., Pandolfi A., et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 169 6 (2006) 2236-2244
45. Knudsen S.T., Foss C.H., Poulsen P.L., et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 49 1 (2003) 39-42
46. Jiang M.Z., Tsukara H., Ohshima Y., et al. Effects of antioxidants and nitric oxide on TNF-alpha-induced adhesion molecule expression and NK-kappaB activation in human dermal microvascular endothelial cells. Life Sci 75 (2004) 1159-1170
47. Tintut Y., Morony S., and Demer L.L. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler Thromb Vasc Biol (2004) e6-e10
48. Yerneni K.K., Rai W., Khan B.V., et al. Hyperglycemia-induced activation of the transcription nuclear factor-kappaB in vascular smooth muscle cells. Diabetes 48 (1999) 855-864
49. Bierhaus A., Schiekofer S., Schwaninger M., et al. Diabetes-associated sustained activation of the transcription nuclear factor-kappaB. Diabetes 50 (2001) 2792-2808
50. Imai S., and Matsue Y. Neuronal regulation of bone metabolism and anabolism: calcitonin gene-related peptide-, substance P-, and tyrosine hydroxylase-containing nerves and the bone. Microsc Res Tech 58 (2002) 61-69
51. Ishizuka K., Hirukawa K., Nakamura H., et al. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. Neurosci Lett 379 1 (2005) 47-51
52. Jeffcoate W. Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link?. Diabetologia 47 9 (2004) 1488-1492
53. Suzuki K., Kurose T., Takizawa M., et al. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. Diabetes Res Clin Pract 68 2 (2005) 117-125
54. Browner W.S., Lui L.Y., and Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86 2 (2001) 631-637
55. Schoppet M., Sattler A.M., Schaefer J.R., et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88 3 (2003) 1024-1028
56. Avignon A., Sultan A., Piot C., et al. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 28 9 (2005) 2176-2180
57. Anand D.V., Lahiri A., Lim E., et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 47 9 (2006) 1850-1857
58. Rasmussen L.M., Tarnow L., Hansen T.K., et al. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 154 1 (2006) 75-81
59. Daroszewska A., and Ralston S.H. Genetics of Paget's disease of bone. Clin Sci 109 3 (2005) 257-263
60. Kimmerle R., and Chantelau E. Weight-bearing intensity produces Charcot deformity in injured neuropathic feet in diabetes. Exp Clin Endocrinol Diabetes 115 6 (2007) 360-364
61. Herbst S.A., Jones J.B., and Saltzman C.L. Pattern of diabetic neuropathic arthropathy associated with the peripheral bone mineral density. J Bone Joint Surg 86 3 (2004) 378-383